Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Gains from Sales and Divestitures (2025)

Evommune (EVMN) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $109436.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $109436.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $109436.0, a N/A change, with the full-year FY2025 number at $109436.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $109436.0 for Q4 2025 at Evommune.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $109436.0 in Q4 2025 to a low of $109436.0 in Q4 2025.